Impact of Commercial Insurance in 2017 – Considerable attention and planning has been focused on the Medicare market, but as we see from the chart below, Medicare represents approximately 13% of the total population. Employer 49% Medicaid 19% Medicare 13% Uninsured 10% Non-Group 6% Other Public 2% (Source: Kaiser Family Foundation) A recent Mercer […]
Health Benefits/Pricing Implosion – The announcement by the Obama administration that it would begin rating health insurance plans based on how many doctors and hospitals they include in their networks along with the announcement the ACA will now (2017) allow the individual deductible to increase to $7150 and $14,300 for family coverage will contribute to a pricing/benefit […]
Many of the 2016 top healthcare market trends began back in 2012-to-2014, and finally emerged more clearly in 2015 for commercially insured populations. This year Access Market Intelligence identifies four (4) major themes emerging that creates the top trends to watch in 2016 into 2017. Themes encapsulating the Top Trends are Macro Issues Trending […]
Published in The Delta Rx Institute/Drake University, Written in collaboration with F. Randy Vogenberg, PhD, RPh Partner, Access Market Intelligence and The National Institute of Collaborative Healthcare Pharmacists are some of the most visible health professionals to the public eye, but they often stand misunderstood by purchasers of health care. They are best known for […]
Employers as Plan Sponsors: Direct to Purchaser, Published at Drake University Delta Rx Institute, Dr. F. Randy Vogenberg, Partner Access Market Intelligence, an affiliate of the National Institute of Collaborative Healthcare Pharmacists are some of the most visible health professionals to the public eye, but they often stand misunderstood by purchasers of health care. They are best known […]
Specialty Drug Wave Hitting Medical and Pharmacy Plans Harder: Trends versus reliable benefit strategy to handle the impact through 2020?The U.S. now has two different markets resulting from implementation of the Affordable Care Act (ACA) and resultant trends. Related to specialty or biological drugs, public sector CMS’s forecast of drug spending is somewhat counterintuitive, given […]
The Anthem Cigna merger: 10 things to Know – Published July 24, 2015 By Tracey Walker, Managed Healthcare Executive Anthem’s acquisition of Cigna is being called the first “merger of titans” by industry watchers. The forces of consolidation are well under way and the merger was not totally unexpected—all of insurance is going through similar […]
Section 1332 Opportunity for Pharmaceutical Manufacturers – by Gregory Judd, CEBS A funny thing happened while pharmaceutical manufacturers were going through wrenching strategic and organizational changes during the past 6 or 7 years. The Affordable Care Act. Ok, so ACA is not all THAT funny. But it IS big, and has exerted a sort of […]